tbuckley/cabot-search huggingface dataset:
S75 The T2R38 bitter taste receptor as a modifier of host response to pseudomonas aeruginosa in cystic fibrosis: does T2R38 genotype impact on clinical infection?
Authors: A Turnbull, H Lund-Palau, R Murphy, A Simbo, A Shoemark, K Wong, A Bush, E Alton, J Davies
Journal: Thorax (2016)

<h3>Background</h3> <i>Pseudomonas aeruginosa</i> (Pa) mediates several virulence factors through quorum sensing (QS). Intriguing <i>in vitro</i> data suggests Pa QS molecules are ‘sensed’ by the T2R38 receptor on airway cilia (J Clin Invest, 2012;122:4145–59), leading to changes in ciliary beat frequency and nitric oxide production, possibly enhancing bacterial clearance. Three polymorphisms occur in the gene coding this receptor, altering the amino acid sequence and receptor function; the functional allele has proline-alanine-valine (PAV); the non-functional allele has alanine-valine-isoleucine (AVI). We hypothesised that the T2R38 receptor may be important in Pa host defence in people with cystic fibrosis (CF) and that T2R38 genotype may modify infection status and clinical outcomes. <h3>Methods</h3> Patients over 6 years with CF were genotyped for polymorphisms in the <i>TAS2R38 </i>gene. Pa infection status was determined by review of all respiratory cultures during 2014 and assigned according to Leeds criteria as chronic, intermittent, Pa free or never. Only patients with ≥3 cultures/year were included in analysis. Lung function data was obtained from CF annual reviews during 2014. <h3>Results</h3> T2R38 receptor genotypes were obtained for 271 patients: 83 (30.6%) AVI/AVI, 44 (16.2%) PAV/PAV, 116 (42.8%) AVI/PAV and 28 (10.3%) AVI/other or PAV/other. Between AVI/AVI, PAV/PAV and AVI/PAV groups there was no significant difference in median age, gender or p.Phe508del <i>CFTR</i> mutation frequency. By T2R38 genotype, there was no significant difference in the proportion of patients in each Pa infection category. In patients with intermittent or chronic Pa there was no significant difference by T2R38 genotype in mean percent predicted FEV<sub>1</sub> or FVC. <h3>Conclusion</h3> T2R38 genotype does not appear to modify Pa infection in people with CF, or to modify lung disease severity in people with CF and intermittent or chronic Pa infection. Further work is underway to investigate T2R38-dependant responses to Pa <i>in vitro</i>.
P1.02-003 ROS1 (D4D6) is Reliable for Immunohisochemistry Detecting of ROS1 Fusion Lung Adenocarcinoma in Malignant Pleural Effusion
Authors: Zheng Wang, Dongge Liu, Yuankai Shi, Xinlin Mu, Xiaohong Han, Li Yang, Jing Di
Journal: Journal of Thoracic Oncology (2017)
Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS.
Authors: Ri ma M. Saliba, Krishna V. Komanduri, Ebru Koca, Amin M. Alousi, Sergio Giralt, Borje S. Andersson, Weiqing Zhang, Gabriela Rondon, Uday R. Popat, Partow Kebriaei, Marcos de Lima, Richard E. Champlin
Journal: Blood (2008)
P78 Tackling emergency lung cancer admissions
Authors: RV Reddy, Y Vali, M Naeem
Journal: Thorax (2016)

<h3>Introduction</h3> A significant proportion of lung cancer patients present as an emergency. This is associated with poor one year survival. Many of these patients have had contact with health services before presenting as an emergency. It is estimated that one in five lung cancer patients have an unplanned admission before their urgent clinic appointment.<sup>1</sup> <h3>Objective</h3> To reduce the number of emergency lung cancer admissions by providing an effective alternative ambulatory pathway for high risk patients. <h3>Methods</h3> Patients referred on the two week wait pathway are vetted by the respiratory physicians. Those identified as having a high risk of admission are prioritised and reviewed urgently on the ambulatory care unit usually by the next working day. Patients with the following features were expedited: Superior vena caval obstruction Liver function abnormalities Large tumour burden on chest radiograph Severe symptoms such as pain and breathlessness Large pleural effusion. Patients with suspected lung cancer presenting to the emergency department were also re-directed to the ambulatory care unit whenever feasible. We evaluated the service for a period of 12 months from October 2014 and compared it with the 12 month period prior to the commissioning of the ambulatory care unit in June 2013. As part of the service, the team developed an innovative lung cancer diagnostic service utilising ultrasound guidance to facilitate early diagnosis. <h3>Results</h3> Table 1 demonstrates the resulting drop in unplanned lung cancer admissions and length of stay. We estimate a cost saving of £170,000 based on a 710 bed-day reduction (£300/bed day) after taking into consideration physician time. If rolled out nationally, reducing the admission rate to 34% of the lung cancer incidence will avoid 6800 admissions (&gt;55,000 bed-days) with significant cost savings and benefits to patients. <h3>Conclusion</h3> Flexible pathways are cost effective and prevent emergency admission of lung cancer patients which is associated with high mortality. This novel approach is easily adoptable widely and would have a significant impact across NHS. <h3>Reference</h3> Tackling emergency presentation of lung cancer: an expert working group report and recommendations. <i>British Lung Foundation</i>, 2015.
MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact
Authors: Shaohua Lu, Takashi Eguchi, Zachary Tano, Daniela Molena, David Jones, William Travis, Prasad Adusumilli
Journal: Journal of Thoracic Oncology (2017)
Phase II Biologic Effects Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Moderate or Mild Hemophilia A or Von Willebrand Disease Unable to Use DDAVP,
Authors: Margaret V. Ragni, Enrico M. Novelli, Anila Murshed, Elizabeth P. Merricks, Mark T. Kloos, Timothy C. Nichols
Journal: Blood (2011)
Respiratory and Ocular Symptoms Among Employees of an Indoor Waterpark Resort — Ohio, 2016
Authors: Sophia K. Chiu, Nancy C. Burton, Kevin H. Dunn, Marie A. de Perio
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

In July 2015, a municipal health department in Ohio received complaints of respiratory and ocular symptoms from patrons of an indoor waterpark resort. In response, the health department conducted an online survey in August 2015 through which 19 (68%) patron and employee respondents reported eye burning, nose irritation, difficulty breathing, and vomiting. On August 11, 2015, the health department requested a health hazard evaluation by CDC's National Institute for Occupational Safety and Health to characterize the prevalence of symptoms among employees and determine the etiology of work-related symptoms. In January 2016, CDC investigators performed a cross-sectional epidemiologic study, environmental sampling, and ventilation system assessment (1). Findings suggested that chlorine disinfection byproducts and environmental conditions contributed to a higher prevalence of work-related respiratory and ocular symptoms among employees in the waterpark compared with employees in other resort areas. Recommendations included servicing the ventilation system, changing work practices to decrease the amount of disinfection byproduct precursors, and responding promptly to employee reports of symptoms.
Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp)
Authors: Robin W. M. Vernooij, Pablo Alonso-Coello, Melissa Brouwers, Laura Martínez García
Journal: PLoS Medicine (2017)

Background Scientific knowledge is in constant development. Consequently, regular review to assure the trustworthiness of clinical guidelines is required. However, there is still a lack of preferred reporting items of the updating process in updated clinical guidelines. The present article describes the development process of the Checklist for the Reporting of Updated Guidelines (CheckUp). Methods and Findings We developed an initial list of items based on an overview of research evidence on clinical guideline updating, the Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument, and the advice of the CheckUp panel (n = 33 professionals). A multistep process was used to refine this list, including an assessment of ten existing updated clinical guidelines, interviews with key informants (response rate: 54.2%; 13/24), a three-round Delphi consensus survey with the CheckUp panel (33 participants), and an external review with clinical guideline methodologists (response rate: 90%; 53/59) and users (response rate: 55.6%; 10/18). CheckUp includes 16 items that address (1) the presentation of an updated guideline, (2) editorial independence, and (3) the methodology of the updating process. In this article, we present the methodology to develop CheckUp and include as a supplementary file an explanation and elaboration document. Conclusions CheckUp can be used to evaluate the completeness of reporting in updated guidelines and as a tool to inform guideline developers about reporting requirements. Editors may request its completion from guideline authors when submitting updated guidelines for publication. Adherence to CheckUp will likely enhance the comprehensiveness and transparency of clinical guideline updating for the benefit of patients and the public, health care professionals, and other relevant stakeholders.
DEMONSTRATION OF LEPRA BACILLI BY ASPIRATION OF NODULES
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P3.03-056 Retrospective Study Comparing Two Frontline Chemotherapy Schemes in Unresectable Malignant Mesothelioma
Authors: Juan Carlos Pardo Ruiz, Yolanda Garcia Garcia, Maria Marin Alcala, Paula Ribera Fernandez, Marta Ferrer Cardona, Clara Martinez Vila, Helena Oliveres Montero De Novoa, Julia Giner Joaquin, Jose Manuel Cabrera Romero, Elsa Dalmau Portulas, Ismael Macias Declara, Eugeni Saigi Grau
Journal: Journal of Thoracic Oncology (2017)
Relationship between Gene Polymorphism of Recipient/ Donor Immune Pathway and Invasive Fungal Infection after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Jimin Shi, Haowen Xiao, Yi Luo, Yamin Tan, Jingsong He, Wanzhuo Xie, Xiujin Ye, Zhen Cai, Maofang Lin, He Huang
Journal: Blood (2014)
Human Pathology: A Textbook.
Authors: A. G. Nicholls
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cushing’s syndrome managed by endoscopic ultrasound-guided radiofrequency ablation of adrenal gland adenoma
Authors: Sun-Ho Lee, Dong Seo, Dongwook Oh, Tae Song, Do Park, Sang Lee, Myung-Hwan Kim
Journal: Endoscopy (2017)

A 38-year-old woman presented with "moon face," "buffalo hump," and weight gain of 9 kg in 12 months. Overnight, 1 mg dexamethasone failed to suppress the morning level of cortisol, and the 24-hour urine cortisol level was elevated to 101 μg/day (normal range 0 – 50). Initial contrast-enhanced abdominal computed tomography (CT) showed a 2.8-cm left adrenal mass enhanced in arterial phase, and the patient was diagnosed with Cushing's syndrome due to left adrenal adenoma ([Fig. 1 a]). She refused surgical treatment but agreed to undergo endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA; STARmed, Koyang, Korea) ([Video 1]).
OA24.06 Histologic Subtype of Early-Stage Lung Adenocarcinoma is a Predictor of Failure Patterns after Stereotactic Body Radiation Therapy
Authors: Jonathan Leeman, Andreas Rimner, Joseph Montecalvo, Meier Hsu, Zhigang Zhang, Donata Von Reibnitz, Kelly Panchoo, Ellen Yorke, Prasad Adusumilli, William Travis, Abraham Wu
Journal: Journal of Thoracic Oncology (2017)
Rapid rational drug targeting of Merkel cell polyomavirus (MCV)-positive Merkel cell carcinoma (MCC) using the survivin inhibitor YM155.
Authors: Reety Arora, Masahiro Shuda, Anna Guastafierro, Tuna Toptan, Yanis Tolstov, Daniel Paul Normolle, Laura Vollmer, Andreas Vogt, Alexander Domling, Jeffrey Brodsky, Yuan Chang, Patrick S. Moore
Journal: Journal of Clinical Oncology (2012)

8577 Background: MCC is an aggressive, chemoresistant skin cancer causing more deaths each year than chronic myelogenous leukemia. We discovered a new virus, Merkel cell polyomavirus (MCV), clonally integrated into ~80% of primary and metastatic MCC in 2008. To find therapeutic targets for this cancer, we examined cellular genes perturbed by MCV infection. Methods: Digital transcriptome subtraction was used to discover MCV and also to reveal survivin gene (BIRC5) upregulation in virus-positive tumors. MCV T antigen knockdown studies in seven MCC lines and large T (LT) transduction into BJ fibroblasts were used to confirm this. Drug screening was performed in vitro using Cell-Titer Glo assays in a two stage analysis. In vivo screening used an MKL-1 (MCV+) MCC NOD-SCIDg mouse xenograft model with a single three-week treatment round. Results: MCV large T oncoprotein induces survivin transcription through retinoblastoma protein sequestration by the LT LXCXE motif. MCV T antigen knockdown results in nonapoptotic MCC cell death and loss of survivin expression. YM155, a phase II survivin transcription inhibitor, causes MCV+ MCC cell necroptosis associated with autophagy at 1-12 nM EC50. Of 1359 other drugs from LOPAC and NCI Oncology Set II libraries, only bortezomib had in vitro potency comparable to YM155. In MKL-1 xenograft studies, mice were treated with saline, bortezomib or YM155 for three weeks using standard dosings. Bortezomib did not significantly improve mouse survival (33%) over saline (24%) during treatment. In contrast, all YM155-treated mice survived (100%, p&lt;0.001) the 3 week treatment period. Tumors resumed growth once YM155 treatment was stopped suggesting that YM155 is cytostatic in vivo rather than cytotoxic. Conclusions: Survivin expression is induced by MCV LT and is critical to MCV+ MCC survival. A survivin inhibitor, YM155 was nontoxic to mice and cytostatic for MCV+ MCC xenografts. Using genomic technologies, in less than four years, the primary viral cause for most MCC was discovered, new diagnostic tests developed and a promising rational drug candidate identified. A cooperative group trial (E1611) for YM155 and bortezomib in MCC patients is currently planned.
Differences in TRA-8 anti-DR5 antibody response with Adriamycin by modulation of Akt, cell cycle and apoptotic pathways.
Authors: Hope Amm, Donald Buchsbaum
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

LB-228 

Introduction: TRA-8 anti-DR5 antibody induces apoptosis in a variety of cancer cell lines both in vitro and in vivo . Breast cancer cell lines have varying sensitivities to TRA-8-mediated apoptosis, but Adriamycin can enhance sensitivity and in some cell lines reverse resistance to TRA-8. We previously reported that TRA-8 induced caspase-3, 8 and 9 cleavage in sensitive 2LMP and LCC6 breast cancer cells, but not in resistant BT474 cells. TRA-8 combined with Adriamycin or Velcade generated caspase cleavage, PARP cleavage and reduced Bid in each cell line. We explored the mechanistic differences among breast cancer cell lines after TRA-8, Adriamycin or combination treatment via modulation of Akt, cell cycle and additional apoptotic pathways. Methods: Cytotoxicity against 2LMP, a TRA-8 sensitive subclone of the MDA-MB-231 cell line, and BT474 resistant breast cancer cells, was detected using an ATPLite assay. Protein expression was detected by Western blot. JC-1 assays measured changes in mitochondria membrane potential. FACS detection of PI staining determined cell cycle phase. Results: Comparisons of phospho-Akt levels between breast cancer cells revealed p-Akt in BT474 with no detection in 2LMP and LCC6 cells. In BT474 cells, p-Akt was reduced with combination TRA-8 and Adriamycin treatment. However, treatment with two Akt inhibitors, including LY294002, did not sensitize BT474 cells to TRA-8 cytotoxicity. Adriamycin induced an accumulation of cells in the G2/M phase of the cell cycle in 2LMP and LCC6 cells. TRA-8 resistant BT474 cells showed S and G2/M arrest in response to Adriamycin. A higher Sub-G1 or apoptotic fraction was detected in the combination Adriamycin and TRA-8 treated cells. Adriamycin increased expression of S and G2 phase cyclins, A and B1 in 2LMP and BT474 cells. However, a cdk/cyclin activating phosphatase, cdc25C was phosphorylated and decreased by Adriamycin in BT474 cells, as well as c-myc. BT474 cells treated with TRA-8 or Adriamycin alone failed to activate apoptotic pathways, but combination treatment did activated apoptosis. Deregulation of the cell cycle by Adriamycin may have allowed for intrinsic apoptotic activation by TRA-8 to proceed with combination treatment. Reduced mitochondrial membrane potential was detected in 2LMP and LCC6 cells treated with TRA-8 alone, with a greater reduction in combination with Adriamycin and only with combination treatment in BT474 cells. Adriamycin reduced expression of Bcl-XL and Mcl-1 in BT474 cells alone and in combination with TRA-8, which removes inhibition of intrinsic apoptosis. Conclusions: Adriamycin reduced constitutive p-Akt in BT474 TRA-8 resistant cells, but inhibition of Akt was not sufficient to sensitize cells. In BT474 breast cancer cells, Adriamycin caused cell cycle arrest, decreased anti-apoptotic proteins and mitochondrial membrane potential, and sensitized cells to TRA-8 induced apoptosis.
Long-term impact of adjuvant versus early salvage radiation therapy on clinical recurrence in PT3N0 prostate cancer patients treated with radical prostatectomy: results of amulti-institutional series
Authors: Nicola Fossati, Jeffrey R Karnes, Alessandro Morlacco, Marco Moschini, Stephen A Boorjian, Thomas Seisen, Alberto Bossi, Cesare Cozzarini, Claudio Fiorino, Barbara Noris Chiorda, Giorgio Gandaglia, Lorenzo Tosco, Dirk De Ridder, Steven Joniau, Gregor Goldner, Shahrokh Francois Shariat, Wolfgang Hinkelbein, Karin Haustermans, Bertrand Tombal, Francesco Montorsi, Hendrik Van Poppel, Thomas Wiegel, Alberto Briganti
Journal: European Urology (2016)
Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate.
Authors: Eyal C. Attar, Daniel J. De Angelo, Andres Sirulnik, Martha Wadleigh, Karen K. Ballen, Kenneth B. Miller, Ilene Galinsky, Donna Neuberg, Elizabeth Trehu, David Schenkein, Richard M. Stone, Philip C. Amrein
Journal: Blood (2005)
Imaging Core Lab Comparison of Five Clinical Liver Iron MRI Methods and Biopsy for Hepatic Iron Concentration (HIC) in Sickle Cell Disease (SCD) Patients.
Authors: J. Wood, J. Heverhagen, X. Yang, G. Jia, R.M. Koch, R. Jacko, S. Sammet, C. Enriquez, A. Nord, P. Allegrini, J. Holland, P.D. Jensen, Y. Gandon, T. Pellas, M. Knopp, P. Cole
Journal: Blood (2006)
PUB129 Optimal Frequency of Tumor Response Evaluation during Palliative Chemotherapy in the Management of Patients with Advanced Thoracic Cancers
Authors: Rajiv Kumar, Jaishree Bhosle, Timothy Yap, Anna Minchom, David Walder, Zohra Ali, Gihan Ratnayake, Nadia Yousaf, Sanjay Popat, Ranga Gunapala, Mary O'Brien
Journal: Journal of Thoracic Oncology (2017)
A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results
Authors: Martino Introna, Alessandra Algarotti, Caterina Micò, Anna Grassi, Alice Pievani, Gianmaria Borleri, Josée Golay, Irene Cavattoni, Sergio Cortelazzo, Alessandro Rambaldi
Journal: Blood (2011)
A FLT3 Gene-Expression Signature Outperforms FLT3 Status in Predicting Clinical Outcome for Patients with Normal Karyotype AML.
Authors: Lars Bullinger, Konstanze Dohner, Christoph Stirner, Frank G. Rucker, Stefan Frohling, Young H. Kim, Richard F. Schlenk, Robert Tibshirani, Hartmut Dohner, Jonathan R. Pollack
Journal: Blood (2006)
In Vivo CpG Administration Accelerates Graft-Versus-Host Disease (GVHD) Lethality by Toll-Like Receptor 9 (TLR9) Ligation of Host Antigen-Presenting Cells (APCs) and Promotes Allogeneic Bone Marrow (BM) Rejection by TLR9 Ligation of Donor APCs.
Authors: Bruce R. Blazar, Angela Panoskaltsis-Mortari, Arthur M. Krieg, Hiroaki Hemmi, Shizuo Akira, Jonathan Serody, William J. Murphy, Patricia A. Taylor
Journal: Blood (2006)
P2.03b-021 Screening for Major Oncogene Alterations in Adenosquamous Lung Carcinoma Using PCR Coupled with Next-Generation and Sanger Sequencing Methods
Authors: Xiaohua Shi, Huanwen Wu, Shafei Wu, Junliang Lu, Huanli Duan, Xuguang Liu, Xuan Zeng, Zhiyong Liang
Journal: Journal of Thoracic Oncology (2017)